The Elastin technology was developed through nearly 20 years of research in the laboratories of Professor Anthony Weiss at the University of Sydney. Since licensing the technology, Elastagen has worked extensively with researchers, clinicians and product consultants in Europe, North America and Australia to further develop and refine the technology. Elastagen has an extensive intellectual property portfolio covering the production, formulation and application of Elastin.

As the world leaders in human Elastin technology, we are the first company to successfully scale up the production of clinical grade GMP manufactured recombinant human tropoelastin, the building block of Elastin. Elastagen operates in compliance with ISO13485 and 21CFR820 and our clinical trial activities are registered under the Australian TGA’s Clinical Trial Notification scheme and run in accordance with the ICH guidelines for Good Clinical Practice.

As we progress our products through the regulatory approval process, we will continue to place a strong emphasis on scientific and clinical excellence and look forward to introducing our promising Elastatherapy™ treatments to the cosmetic and medical dermatology markets worldwide.